Expression of PD-L1 and whole-exome sequencing (WES)-based mutation profiling of tissues
tumor, tumors
MICROSATELLITE INSTABILITY HIGH, TUMOR, TUMORS
Immunohistochemical (IHC) examination of PD-L1 and PD-1 expression was performed. A total of 46.7% (14/30) of patients had tumors that were PD-L1 positive [tumor area positivity (TAP) ≥ 1% was defined as positive, proportion of tumor and/or immune cells with PD-L1 staining at any intensity].Representative case with different expression of PD-L1 protein and DDR mutation of each patient. To further investigate the molecular mechanism of action of the combined therapy in advanced ICC, WES were analyzed in 30 subjects. A total of 1564 nonsynonymous mutations were observed in 30 patients. The median tumor mutation burden (TMB) was 0.985 Muts/Mb (range, 0.08–31.82 Muts/Mb). Two patients presented with microsatellite instability high (MSI-h), and three patients had MSI-l (Table 